Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Denmark has engaged with patients on biosimilars.
Transcript
What we have done in Denmark is, actually, we have taken the patients onboard. In the decision-making process, we have developed information for patients, which has been done by the authorities, not by companies, but by the authorities in cooperation with the patients. They have not been able to dictate the contents, but their concerns and their questions have been taken into consideration and have been answered.
If you look, for instance, at the website of the Danish Medicines Agency, you will see some very convincing “yes” answers or “no” answers to some of the most normal questions that patients might have about biosimilars.
But I think the main thing is to explain to people that, no, you’re not getting a new treatment. You’re not getting a new product. You’re simply getting another producer at a much lower price. It’s not a new treatment. It’s not really switching in the sense where we normally use that word.
Language is of course important. It’s very, if you will, uphill to try to change people’s perception of language and what you interpret when you use special words. That is also true in this area.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.